Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Recruiting · NCT06353997 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-09-16 | NCT06353997 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Inhibrx Biosciences, Inc | 5 |
| Providence Health & Services | 35 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ellison Institute of Technology (EITM) | Los Angeles | United States | 1 |
| Providence Portland Cancer Institute - Franz Clinic | Portland | United States | 4 |
| Providence St. Vincent Medical Center | Portland | United States | 35 |